Symbols / SPRY Stock $7.44 -6.30% ARS Pharmaceuticals, Inc.
SPRY (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Ratings
Current target
$7.44
Low
$12.00
High
$34.00
Mean
$26.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-04 | init | Roth Capital | — → Buy | $40 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $30 |
| 2025-01-14 | main | Raymond James | Strong Buy → Strong Buy | $28 |
| 2025-01-13 | main | Leerink Partners | Outperform → Outperform | $27 |
| 2024-10-08 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-09-20 | main | Leerink Partners | Outperform → Outperform | $25 |
| 2024-09-16 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-09-09 | reit | Cantor Fitzgerald | Overweight → Overweight | $30 |
| 2024-08-20 | init | Cantor Fitzgerald | — → Overweight | $30 |
| 2024-08-13 | up | Raymond James | Outperform → Strong Buy | $22 |
| 2024-07-25 | init | Raymond James | — → Outperform | $18 |
| 2024-03-11 | reit | Wedbush | Outperform → Outperform | $19 |
| 2024-03-05 | up | Leerink Partners | Market Perform → Outperform | $18 |
| 2023-11-13 | main | Wedbush | Outperform → Outperform | $13 |
| 2023-09-21 | main | Wedbush | Outperform → Outperform | $5 |
| 2023-09-20 | down | William Blair | Outperform → Market Perform | — |
| 2023-08-14 | reit | Wedbush | Outperform → Outperform | $15 |
| 2023-06-21 | main | Wedbush | Outperform → Outperform | $15 |
| 2023-05-18 | reit | Wedbush | Outperform → Outperform | $17 |
| 2023-05-12 | reit | Wedbush | Outperform → Outperform | $17 |
- Needle-free allergy spray neffy hits $17.5M in U.S. Q1 sales - Stock Titan Fri, 15 May 2026 10
- ARS PHARMACEUTICALS ($SPRY) Releases Q1 2026 Earnings - Quiver Quantitative Fri, 15 May 2026 10
- SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill ue, 12 May 2026 07
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Fri, 15 May 2026 11
- Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss - marketscreener.com Fri, 15 May 2026 10
- ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A - Benzinga Fri, 15 May 2026 06
- ARS Pharmaceuticals Appoints Donn Casale as New President - The Globe and Mail hu, 14 May 2026 12
- ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment - ChartMill Fri, 15 May 2026 11
- SPRY: Q1 revenue hit $22.7M as neffy adoption accelerated, with breakeven targeted by mid-2027 - TradingView Fri, 15 May 2026 15
- ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss - Investing.com Nigeria Fri, 15 May 2026 10
- Neffy launch drives ARS Pharmaceuticals (NASDAQ: SPRY) Q1 revenue jump - Stock Titan Fri, 15 May 2026 10
- How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And Approvals - Yahoo Finance Sat, 02 May 2026 07
- SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView Fri, 15 May 2026 16
- Needle-free allergy spray maker ARS Pharma brings in new president - Stock Titan Wed, 13 May 2026 12
- ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance Mon, 02 Mar 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
84.28
-5.46%
|
89.15
+297063.33%
|
0.03
-97.72%
|
1.32
|
| Operating Revenue |
|
84.28
-5.46%
|
89.15
+297063.33%
|
0.03
-97.72%
|
1.32
|
| Cost Of Revenue |
|
20.42
+1990.38%
|
0.98
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
20.42
+1990.38%
|
0.98
|
0.00
|
—
|
| Gross Profit |
|
63.85
-27.58%
|
88.17
+293806.67%
|
0.03
|
—
|
| Operating Expense |
|
243.30
+166.62%
|
91.25
+35.09%
|
67.55
+83.40%
|
36.83
|
| Research And Development |
|
13.18
-32.68%
|
19.58
-3.38%
|
20.27
+10.29%
|
18.38
|
| Selling General And Administration |
|
230.12
+221.06%
|
71.67
+51.58%
|
47.28
+156.20%
|
18.46
|
| General And Administrative Expense |
|
—
|
—
|
47.28
+156.20%
|
18.46
|
| Other Gand A |
|
—
|
—
|
47.28
+156.20%
|
18.46
|
| Total Expenses |
|
263.73
+185.94%
|
92.23
+36.54%
|
67.55
+83.40%
|
36.83
|
| Operating Income |
|
-179.45
-5720.56%
|
-3.08
+95.43%
|
-67.52
-90.11%
|
-35.52
|
| Total Operating Income As Reported |
|
-179.45
-5720.56%
|
-3.08
+95.43%
|
-67.52
-90.11%
|
-35.52
|
| EBITDA |
|
-168.78
-2136.92%
|
8.29
+112.27%
|
-67.52
-91.83%
|
-35.20
|
| Normalized EBITDA |
|
-168.78
-2136.92%
|
8.29
+112.27%
|
-67.52
-92.60%
|
-35.06
|
| Reconciled Depreciation |
|
-4.16
+42.08%
|
-7.17
-5.90%
|
-6.78
-2223.82%
|
0.32
|
| EBIT |
|
-168.78
-2136.92%
|
8.29
+112.27%
|
-67.52
-90.11%
|
-35.52
|
| Total Unusual Items |
|
—
|
—
|
—
|
-0.14
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
-0.14
|
| Net Income |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Pretax Income |
|
-171.38
-2168.28%
|
8.29
+115.24%
|
-54.37
-56.75%
|
-34.68
|
| Net Non Operating Interest Income Expense |
|
8.07
-29.02%
|
11.37
|
—
|
—
|
| Interest Expense Non Operating |
|
2.60
|
0.00
|
—
|
—
|
| Net Interest Income |
|
8.07
-29.02%
|
11.37
|
—
|
—
|
| Interest Expense |
|
2.60
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
10.67
-6.16%
|
11.37
|
—
|
—
|
| Interest Income |
|
10.67
-6.16%
|
11.37
|
—
|
—
|
| Other Income Expense |
|
—
|
11.37
-13.58%
|
13.15
+1477.34%
|
0.83
|
| Other Non Operating Income Expenses |
|
—
|
11.37
-13.58%
|
13.15
+1250.62%
|
0.97
|
| Gain On Sale Of Security |
|
—
|
—
|
—
|
-0.14
|
| Tax Provision |
|
-0.08
-127.78%
|
0.29
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
-98.66%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Net Income From Continuing Operation Net Minority Interest |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Net Income From Continuing And Discontinued Operation |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Net Income Continuous Operations |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Normalized Income |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-57.39%
|
-34.54
|
| Net Income Common Stockholders |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Diluted EPS |
|
—
|
0.08
+114.04%
|
-0.57
+34.48%
|
-0.87
|
| Basic EPS |
|
—
|
0.08
+114.04%
|
-0.57
+34.48%
|
-0.87
|
| Basic Average Shares |
|
—
|
96.94
+1.81%
|
95.22
+138.30%
|
39.96
|
| Diluted Average Shares |
|
—
|
102.39
+7.54%
|
95.22
+138.30%
|
39.96
|
| Diluted NI Availto Com Stockholders |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
327.65
-6.69%
|
351.15
+50.59%
|
233.19
-17.14%
|
281.44
|
| Current Assets |
|
284.90
-14.78%
|
334.30
+44.26%
|
231.73
-16.56%
|
277.70
|
| Cash Cash Equivalents And Short Term Investments |
|
244.99
-21.98%
|
314.02
+37.51%
|
228.36
-16.77%
|
274.38
|
| Cash And Cash Equivalents |
|
41.32
-18.69%
|
50.82
-28.40%
|
70.97
-66.29%
|
210.52
|
| Other Short Term Investments |
|
203.67
-22.62%
|
263.20
+67.23%
|
157.39
+146.45%
|
63.86
|
| Receivables |
|
25.35
+210.06%
|
8.18
+1091.69%
|
0.69
-32.01%
|
1.01
|
| Accounts Receivable |
|
25.35
+210.06%
|
8.18
|
0.00
|
—
|
| Other Receivables |
|
—
|
—
|
0.11
-48.83%
|
0.21
|
| Accrued Interest Receivable |
|
—
|
0.99
+43.88%
|
0.69
-13.82%
|
0.80
|
| Inventory |
|
8.37
+60.57%
|
5.21
|
0.00
|
—
|
| Finished Goods |
|
—
|
5.21
|
0.00
|
—
|
| Prepaid Assets |
|
6.19
-10.05%
|
6.89
+239.55%
|
2.03
-12.21%
|
2.31
|
| Other Current Assets |
|
—
|
1.23
+88.96%
|
0.65
|
—
|
| Total Non Current Assets |
|
42.76
+153.62%
|
16.86
+1053.08%
|
1.46
-60.86%
|
3.73
|
| Net PPE |
|
2.46
+131.24%
|
1.07
+29.37%
|
0.82
+6.46%
|
0.77
|
| Gross PPE |
|
—
|
1.27
+33.97%
|
0.94
+14.96%
|
0.82
|
| Accumulated Depreciation |
|
—
|
-0.20
-65.29%
|
-0.12
-152.08%
|
-0.05
|
| Properties |
|
—
|
0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
—
|
0.26
+214.81%
|
0.08
|
—
|
| Other Properties |
|
—
|
0.99
+17.50%
|
0.84
+2.19%
|
0.82
|
| Leases |
|
—
|
0.02
+0.00%
|
0.02
|
—
|
| Goodwill And Other Intangible Assets |
|
14.45
+96.07%
|
7.37
+1094.65%
|
0.62
|
0.00
|
| Other Intangible Assets |
|
14.45
+96.07%
|
7.37
+1094.65%
|
0.62
|
—
|
| Non Current Prepaid Assets |
|
—
|
2.80
+13233.33%
|
0.02
-99.29%
|
2.96
|
| Other Non Current Assets |
|
25.84
+206.84%
|
8.42
|
—
|
2.96
|
| Total Liabilities Net Minority Interest |
|
213.39
+126.16%
|
94.36
+3786.12%
|
2.43
-71.60%
|
8.55
|
| Current Liabilities |
|
39.15
+67.00%
|
23.44
+880.34%
|
2.39
-56.08%
|
5.44
|
| Payables And Accrued Expenses |
|
37.95
+66.14%
|
22.84
+1142.03%
|
1.84
-58.99%
|
4.48
|
| Payables |
|
5.72
-42.00%
|
9.87
+1200.40%
|
0.76
-58.59%
|
1.83
|
| Accounts Payable |
|
5.72
-42.00%
|
9.87
+1200.40%
|
0.76
-54.25%
|
1.66
|
| Other Payable |
|
—
|
—
|
0.15
-84.52%
|
1.00
|
| Current Accrued Expenses |
|
32.22
+148.42%
|
12.97
+1101.02%
|
1.08
-59.26%
|
2.65
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
2.29
+627.94%
|
0.32
-29.53%
|
0.45
|
| Total Tax Payable |
|
—
|
—
|
0.00
-97.70%
|
0.17
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.04
-82.28%
|
0.24
+3.04%
|
0.23
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.04
-82.28%
|
0.24
+3.04%
|
0.23
|
| Current Deferred Liabilities |
|
0.61
+9.34%
|
0.56
|
0.00
-100.00%
|
0.28
|
| Current Deferred Revenue |
|
0.61
+9.34%
|
0.56
|
0.00
-100.00%
|
0.28
|
| Other Current Liabilities |
|
0.59
+1300.00%
|
0.04
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
174.25
+145.72%
|
70.92
+191562.16%
|
0.04
-98.81%
|
3.10
|
| Long Term Debt And Capital Lease Obligation |
|
96.37
|
0.00
-100.00%
|
0.04
-85.26%
|
0.25
|
| Long Term Debt |
|
96.37
|
—
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.04
-85.26%
|
0.25
|
| Non Current Deferred Liabilities |
|
1.13
-26.24%
|
1.53
|
0.00
-100.00%
|
2.85
|
| Non Current Deferred Revenue |
|
1.13
-26.24%
|
1.53
|
0.00
-100.00%
|
2.85
|
| Other Non Current Liabilities |
|
72.14
+3.97%
|
69.38
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
0.00
|
| Stockholders Equity |
|
114.26
-55.51%
|
256.80
+11.28%
|
230.76
-15.44%
|
272.89
|
| Common Stock Equity |
|
114.26
-55.51%
|
256.80
+11.28%
|
230.76
-15.44%
|
272.89
|
| Capital Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+11.11%
|
0.01
|
| Common Stock |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+11.11%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
99.29
+1.36%
|
97.95
+1.60%
|
96.41
+2.63%
|
93.94
|
| Ordinary Shares Number |
|
99.29
+1.36%
|
97.95
+1.60%
|
96.41
+2.63%
|
93.94
|
| Additional Paid In Capital |
|
408.73
+7.60%
|
379.87
+4.94%
|
362.00
+3.60%
|
349.41
|
| Retained Earnings |
|
-294.60
-138.92%
|
-123.31
+6.09%
|
-131.30
-70.66%
|
-76.94
|
| Gains Losses Not Affecting Retained Earnings |
|
0.12
-43.18%
|
0.22
+348.98%
|
0.05
-87.96%
|
0.41
|
| Other Equity Adjustments |
|
0.12
-43.18%
|
0.22
+348.98%
|
0.05
-87.96%
|
0.41
|
| Total Equity Gross Minority Interest |
|
114.26
-55.51%
|
256.80
+11.28%
|
230.76
-15.44%
|
272.89
|
| Total Capitalization |
|
210.63
-17.98%
|
256.80
+11.28%
|
230.76
-15.44%
|
272.89
|
| Working Capital |
|
245.75
-20.94%
|
310.86
+35.55%
|
229.34
-15.76%
|
272.26
|
| Invested Capital |
|
210.63
-17.98%
|
256.80
+11.28%
|
230.76
-15.44%
|
272.89
|
| Total Debt |
|
96.37
+229361.90%
|
0.04
-84.67%
|
0.27
-43.04%
|
0.48
|
| Net Debt |
|
55.06
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
—
|
0.04
-84.67%
|
0.27
-43.04%
|
0.48
|
| Net Tangible Assets |
|
99.81
-59.99%
|
249.43
+8.38%
|
230.14
-15.66%
|
272.89
|
| Tangible Book Value |
|
99.81
-59.99%
|
249.43
+8.38%
|
230.14
-15.66%
|
272.89
|
| Current Notes Payable |
|
—
|
—
|
—
|
0.00
|
| Derivative Product Liabilities |
|
—
|
—
|
—
|
0.00
|
| Non Current Accrued Expenses |
|
4.61
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-170.87
-1361.19%
|
13.55
+122.86%
|
-59.27
-47.88%
|
-40.08
|
| Cash Flow From Continuing Operating Activities |
|
-170.87
-1361.19%
|
13.55
+122.86%
|
-59.27
-47.88%
|
-40.08
|
| Net Income From Continuing Operations |
|
-171.30
-2241.76%
|
8.00
+114.71%
|
-54.37
-56.75%
|
-34.68
|
| Depreciation Amortization Depletion |
|
-4.16
+42.08%
|
-7.17
-5.90%
|
-6.78
-2223.82%
|
0.32
|
| Depreciation |
|
1.37
+1630.38%
|
0.08
+8.22%
|
0.07
+114.71%
|
0.03
|
| Amortization Cash Flow |
|
-5.52
+23.86%
|
-7.25
-5.93%
|
-6.85
-2502.81%
|
0.28
|
| Depreciation And Amortization |
|
-4.16
+42.08%
|
-7.17
-5.90%
|
-6.78
-2223.82%
|
0.32
|
| Amortization Of Intangibles |
|
-5.52
+23.86%
|
-7.25
-5.93%
|
-6.85
-2502.81%
|
0.28
|
| Other Non Cash Items |
|
0.34
|
—
|
—
|
1.06
|
| Stock Based Compensation |
|
22.09
+52.02%
|
14.53
+57.38%
|
9.23
+58.05%
|
5.84
|
| Provisionand Write Offof Assets |
|
2.16
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
—
|
—
|
0.14
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
0.14
|
| Change In Working Capital |
|
-20.00
-1005.80%
|
-1.81
+75.42%
|
-7.36
+42.28%
|
-12.75
|
| Change In Receivables |
|
-17.20
-110.46%
|
-8.18
|
0.00
|
—
|
| Changes In Account Receivables |
|
-17.20
-110.46%
|
-8.18
|
0.00
|
—
|
| Change In Inventory |
|
-21.99
-269.82%
|
-5.95
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.66
+110.60%
|
-6.19
-331.43%
|
-1.44
-20.99%
|
-1.19
|
| Change In Payables And Accrued Expense |
|
18.88
+15.04%
|
16.41
+691.03%
|
-2.78
+73.00%
|
-10.29
|
| Change In Other Working Capital |
|
-0.35
-116.75%
|
2.09
+166.34%
|
-3.15
-145.44%
|
-1.28
|
| Change In Other Current Assets |
|
—
|
—
|
—
|
—
|
| Investing Cash Flow |
|
56.77
+153.50%
|
-106.10
-21.70%
|
-87.18
-43709.05%
|
-0.20
|
| Cash Flow From Continuing Investing Activities |
|
56.77
+153.50%
|
-106.10
-21.70%
|
-87.18
-43709.05%
|
-0.20
|
| Net PPE Purchase And Sale |
|
-0.34
+39.79%
|
-0.56
-221.71%
|
-0.17
+12.06%
|
-0.20
|
| Purchase Of PPE |
|
-0.34
+39.79%
|
-0.56
-221.71%
|
-0.17
+12.06%
|
-0.20
|
| Capital Expenditure |
|
-0.34
+39.79%
|
-0.56
-221.71%
|
-0.17
+12.06%
|
-0.20
|
| Net Investment Purchase And Sale |
|
64.97
+166.27%
|
-98.04
-12.68%
|
-87.00
|
0.00
|
| Purchase Of Investment |
|
-242.03
+32.02%
|
-356.04
-30.89%
|
-272.00
|
0.00
|
| Sale Of Investment |
|
307.00
+18.99%
|
258.00
+39.46%
|
185.00
|
0.00
|
| Net Other Investing Changes |
|
-7.86
-4.80%
|
-7.50
|
—
|
—
|
| Financing Cash Flow |
|
104.60
+44.47%
|
72.40
+949.41%
|
6.90
-96.38%
|
190.73
|
| Cash Flow From Continuing Financing Activities |
|
104.60
+44.47%
|
72.40
+949.41%
|
6.90
-96.38%
|
190.73
|
| Net Issuance Payments Of Debt |
|
96.26
|
0.00
|
0.00
+100.00%
|
-8.68
|
| Issuance Of Debt |
|
96.26
|
0.00
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-8.68
|
| Long Term Debt Issuance |
|
96.26
|
0.00
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-8.68
|
| Net Long Term Debt Issuance |
|
96.26
|
0.00
|
0.00
+100.00%
|
-8.68
|
| Proceeds From Stock Option Exercised |
|
5.68
+88.36%
|
3.02
-56.28%
|
6.90
+1110.35%
|
0.57
|
| Net Other Financing Charges |
|
2.66
-96.17%
|
69.38
|
—
|
198.84
|
| Changes In Cash |
|
-9.50
+52.86%
|
-20.15
+85.56%
|
-139.55
-192.75%
|
150.46
|
| Beginning Cash Position |
|
50.82
-28.40%
|
70.97
-66.29%
|
210.52
+250.50%
|
60.06
|
| End Cash Position |
|
41.32
-18.69%
|
50.82
-28.40%
|
70.97
-66.29%
|
210.52
|
| Free Cash Flow |
|
-171.21
-1418.48%
|
12.98
+121.85%
|
-59.44
-47.58%
|
-40.28
|
| Interest Paid Supplemental Data |
|
2.45
|
0.00
|
0.00
-100.00%
|
0.37
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-15 View
- 8-K2026-05-15 View
- 8-K2026-05-13 View
- 10-K2026-03-09 View
- 8-K2026-03-09 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42025-11-14 View
- 42025-11-14 View
- 42025-11-14 View
- 10-Q2025-11-10 View
- 8-K2025-11-10 View
- 8-K2025-09-29 View
- 8-K2025-08-28 View
- 42025-08-22 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|